Jupiter Neurosciences Tapped to Showcase Phase IIa and Nugevia™ Updates at Mar-a-Lago Investor Dinner
Jupiter Neurosciences will present its clinical and commercial progress at an invitation-only investor dinner on February 25, 2026 at Mar-a-Lago Club in Palm Beach. Senior management plans to update high-net-worth attendees on Phase IIa Parkinson’s trial advancement, broader neuroinflammation pipeline initiatives and Nugevia™ commercial execution.
1. Exclusive Mar-a-Lago Presentation
Jupiter Neurosciences has been invited as the only company to present at a private investor dinner at Mar-a-Lago Club, Palm Beach, on February 25, 2026, targeting accredited and high-net-worth investors with an intimate discussion format.
2. Clinical Progress Updates
Senior management will review recent clinical achievements, including advancement of the Phase IIa Parkinson’s disease trial and broader development initiatives across its neuroinflammation pipeline to highlight scientific progress and upcoming study milestones.
3. Commercial Execution of Nugevia™
Executives will outline the commercial rollout and revenue growth of Nugevia™, the company’s patented JOTROL™-based resveratrol platform, emphasizing sales performance, distribution channels and planned market expansion.
4. Investor Engagement Strategy
The event underscores Jupiter’s ongoing strategy of combining clinical development with active commercial revenue generation, reinforcing management’s commitment to transparent investor engagement and signaling further presentations and meetings ahead.